期刊
DRUG DISCOVERY TODAY
卷 24, 期 2, 页码 428-439出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.11.003
关键词
-
资金
- French National Institute for Health and Medical Research (INSERM)
- French National Institute for Health and Medical Research (INSERM), the University Paris-Sud
- French National Institute for Health and Medical Research (INSERM), University Paris-Saclay
- Chancellerie des Universites de Paris (Legs Poix)
- French National Agency for Research (ANR) [ANR-16-CE17 0014]
- Fondation de la Recherche Medicale (FRM) [DEQ20150331712]
- Departement Hospitalo-Universitaire (DHU) Thorax Innovation (TORINO)
- Assistance Publique-Hopitaux de Paris (AP-HP)
- Service de Pneumologie
- Centre de Reference de l'Hypertension Pulmonaire Severe
- LabEx LERMIT [ANR-10-LABX-0033]
- French PAH patient association (HTAP France)
- french Fonds de Dotation 'Recherche en Sante Respiratoire' - (FRSR) - Fondation du Souffle (FdS)
- Agence Nationale de la Recherche (ANR) [ANR-16-CE17-0014] Funding Source: Agence Nationale de la Recherche (ANR)
Macrophage migration inhibitory factor (MIF) is a protein that acts as a cytokine-, enzyme-, endocrine- and chaperon-like molecule. It binds to the cell-surface receptor CD74 in association with CD44, which activates the downstream signal transduction pathway. In addition, MIF acts also as a noncognate ligand for C-X-C chemokine receptor type 2 (CXCR2), type 4 (CXCR4), and type 7 (CXCR7). Recently, D-dopachrome tautomerase (DDT), a second member of the MIF superfamily, was identified. From a pharmacological and clinical point of view, the nonredundant biological properties of MIF and D-DT anticipate potential synergisms from their simultaneous inhibition. Here, we focus on the role of MIF and D-DT in human immune-inflammatory, autoimmune, and chronic respiratory diseases, providing an update on the progress made in the identification of specific small-molecule inhibitors of these proteins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据